Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from The United Laboratories International Holdings ( (HK:3933) ) is now available.
The United Laboratories reported 2025 revenue of RMB13.21 billion, down 4% year on year, with profit attributable to shareholders falling 21.6% to RMB2.09 billion and basic earnings per share declining to RMB1.1065. The board proposed a final dividend of RMB0.26 per share, taking the full-year payout to RMB0.42 and implying a reduced payout ratio of 38%, reflecting more cautious capital distribution amid weaker earnings.
Against a backdrop of intensifying Chinese policy support for innovative drugs, the group is doubling down on an innovation-led strategy that prioritises high-end R&D and globalisation. It now has 23 Class I new drug candidates under development, including UBT251 and UBT37034 injections for obesity, diabetes, MASH and chronic kidney disease, with advancing clinical programmes in China and the U.S. expected to support its long-term transformation and competitive position despite near-term profit pressure.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings is a Mainland China-based pharmaceutical group listed in Hong Kong, engaged in the research, development, manufacturing and sale of drugs. The company focuses on innovative Class I drug candidates and generic medicines, with a growing emphasis on obesity, diabetes, metabolic and kidney disease treatments and international market expansion.
Average Trading Volume: 11,348,779
Technical Sentiment Signal: Hold
Current Market Cap: HK$19.93B
Learn more about 3933 stock on TipRanks’ Stock Analysis page.